Chugai Seiyaku Kabushiki Kaisha

F. Hoffmann-la Roche Ag

Kyoko Takami

Hiroki Nishii

Lisha Wang

Masayuki Matsushita

Tadakatsu Hayase

Yoshito Nakanishi

Hirosato Ebiike

WeiLi Zhao

Masayuki Ohmori

Masami Kochi

Toshiyuki Mio

Naoki Taka

Ikumi Hyodo

Weili Zhao

A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a Caryl group; Rand Rindependently represent H, OH, X, CN, NO, a Chaloalkyl group, a Calkyl group, or the like &#x3c;Rand Rtogether form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group&#x3e;; Rrepresents H, a Calkyl group, a Caryl group, a Calkyl group, or a Chaloalkyl group; and Rrepresents H, X, a Calkyl group, a Chaloalkyl group, OH, CN, NO, or the like. 

Aminopyrazole derivative

A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a Caryl group; Rand Rindependently represent H, OH, X, CN, NO, a Chaloalkyl group, a Calkyl group, or the like &#x3c;Rand Rtogether form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group&#x3e;; Rrepresents H, a Calkyl group, a Caryl group, a Calkyl group, or a Chaloalkyl group; and Rrepresents H, X, a Calkyl group, a Chaloalkyl group, OH, CN, NO, or the like.) 

Growing community of inventors

Shizuoka, Japan

Kyoko Takami